Background: Glyoxalase 1 (GLO1) is an enzyme that metabolizes methylglyoxal (MG), which is a competitive partial agonist at GABA A receptors. Inhibition of GLO1 increases concentrations of MG in the brain and decreases binge-like ethanol (EtOH) drinking. This study assessed whether inhibition of GLO1, or genetic overexpression of Glo1, would also alter the locomotor effects of EtOH, which might explain reduced EtOH consumption following GLO1 inhibition. We used the prototypical GABA A receptor agonist muscimol as a positive control.
A LCOHOL USE DISORDERS (AUDs) affect more than 15 million people in the United States alone (Center for Behavioral Health Statistics and Quality, 2016) and impose a cost of $249 billion annually (Sacks et al., 2015) . Currently, there are only 3 FDA-approved medications to treat AUD, and these treatments are only effective in a subset of individuals (e.g., Garbutt, 2009; Maisel et al., 2013; Snyder and Bowers, 2008) . Consequently, there is a significant need for novel therapeutic targets for AUD.
One possible target is glyoxalase 1 (GLO1; McMurray et al., 2017) . GLO1 is a ubiquitously expressed enzyme that metabolizes the glycolytic by-product methylglyoxal (MG).
We have previously shown that MG acts as a competitive partial agonist at GABA A receptors (Distler et al., 2012) . Pharmacological inhibition of GLO1 results in elevated MG levels in the brain, thus, increasing GABAergic tone. Inhibition of GLO1 decreased binge-like ethanol (EtOH) drinking in mice during a drinking in the dark paradigm, as well as various anxiety-and depression-like behaviors (Distler et al., 2012; McMurray et al., 2017 McMurray et al., , 2018 . In addition, transgenic overexpression of Glo1 increased EtOH drinking (McMurray et al., 2017) .
Substantial previous work with various GABAergic agonists and positive allosteric modulators indicates that compounds that increase GABAergic activity can produce additive effects when administered with EtOH. Specifically, it has been well-established that enhanced locomotor sedation and ataxia are observed when EtOH and GABAergic agonists or positive modulators are co-administered (e.g., Dudek and Phillips, 1989; Holstein et al., 2009; Saeed Dar, 2006; Tran et al., 2017; Vanover et al., 1999) . Additive locomotor effects with EtOH could potentially explain a compound's ability to reduce EtOH consumption due to an increase in competing behaviors (e.g., locomotor activation) or through increased sedative effects that limit consumption. In humans, locomotor stimulatory effects of EtOH are associated with euphoria and drug-liking, whereas sedation is associated with more negative/aversive drug responses (Fridberg et al., 2017; King et al., 2011) . Thus, measurements of EtOH-induced changes in locomotor behavior may also provide some insight into sensitivity to EtOH's subjective effects.
We have shown previously that GLO1 inhibition does not alter the duration of EtOH-induced loss of righting reflex or ataxia as assessed by footslips on a balance beam (McMurray et al., 2017) . However, these studies only considered 1 EtOH dose and did not measure locomotor activity. Consequently, we sought to explore whether increased GLO1 inhibition (and subsequently increased GABA A receptor activation) produced additive effects on locomotor behavior when co-administered with a range of EtOH doses, thereby providing a possible explanation for the previously observed reductions in EtOH consumption. To test this hypothesis, we assessed the effects of GLO1 inhibition on the locomotor response to different doses of EtOH. As a positive control, we also assessed the effects of the nonselective GABA A agonist muscimol, which has been previously shown to potentiate the sedative effects of EtOH (Holstein et al., 2009 ). We selected doses of S-bromobenzylglutathione cyclopentyl diester (pBBG) and muscimol that had been previously shown to inhibit EtOH drinking (McMurray et al., 2017; Quoilin and Boehm, 2016) . To further explore whether GLO1 alterations affect the locomotor response to EtOH, we also assessed the effect of Glo1 overexpression on the locomotor response to EtOH. Transgenic mice overexpressing Glo1 on an FVB/NJ (FVB) genetic background have been previously shown to have greater binge-like EtOH intake than wildtype littermates (McMurray et al., 2017) and have lower brain MG concentrations (Distler et al., 2012) . If MG and EtOH act additively on EtOH locomotor response, then we would expect Glo1 transgenic mice to be less sensitive to the locomotor effects of EtOH. Additionally, because Glo1 genetic and pharmacological manipulations have been shown previously to alter anxiety-like behavior (i.e., Glo1 overexpression increases anxiety-like behavior and GLO1 inhibition decreases it; Distler et al., 2012) , we also measured anxiety-like behavior in these studies to assess potential treatment interactions with EtOH anxiolytic response.
MATERIALS AND METHODS

Animals and Husbandry
For Experiments 1 and 2, 8-week-old male C57BL/6J (B6) mice were ordered from the Jackson Laboratory (Bar Harbor, ME). All mice were between 65 and 74 days of age at the time of testing. For Experiment 3, male and female mice heterozygous for Glo1 overexpression on a FVB background and wild-type littermates were bred in house. Generation of the Glo1 transgenic mice by insertion of a BAC transgene has been previously described (Distler et al., 2012) . Mice in Experiment 3 were between 57 and 139 days of age at the time of testing. For all experiments, mice were housed 2 to 5 per cage on cob bedding and food (Envigo 8604; Indianapolis, IN) and water was provided ad libitum. Mice were maintained on a 12 h/ 12-h light/dark cycle with lights on at 06:00. Behavioral testing was conducted during the light phase. All procedures were approved by the local Institutional Animal Care and Use Committees and were conducted in accordance with the NIH Guidelines for the Care and Use of Laboratory Animals.
Open Field Testing and Apparatus
Mice were moved into the testing room and allowed to acclimate for at least 30 minutes prior to testing. Locomotor behavior was measured using an open field test, which has been described previously (McMurray et al., 2016) . Briefly, mice were placed in the center of a square chamber (43 9 43 9 33 cm) (Accusan, Columbus, OH) with dim overhead lighting inside of sound-and light-attenuating boxes and allowed to freely explore for 30 minutes. A grid of infrared detection beams in each chamber and Versamax software (Omnitech Electronics, Columbus, OH) was used to track animal location and locomotor activity (distance traveled) during the test. Although not directly related to the main hypothesis of these experiments, we also chose to record time spent in the center zone (26 9 26 cm) as a measure of anxiety-like behavior to assess potential interactions between the GLO1 manipulations and EtOHinduced anxiolytic response, as both GLO1 inhibition and EtOH can produce anxiolytic effects. The chambers were wiped down with isopropyl alcohol between each animal and eliminate odors.
Drugs
The GLO1 inhibitor pBBG was synthesized in the laboratory of Alexander Arnold at the University of Wisconsin Milwaukee, as previously described (McMurray et al., 2017) . The pBBG dose (7.5 mg/kg) was chosen because it is in the range shown to reduce binge-like EtOH drinking (6.25 to 12.5 mg/kg; McMurray et al., 2017) . pBBG was dissolved in vehicle (8% DMSO/18% Tween 80/ saline) and administered i.p. (injection volume 0.01 ml/g). The pBBG pretreatment was given 2 hours before testing, consistent with previous studies demonstrating pBBG effects on EtOH drinking, anxiety-like, and depression-like behaviors (Distler et al., 2012; McMurray et al., 2017 McMurray et al., , 2018 . Muscimol was purchased from Sigma-Aldrich (St. Louis, MO). The muscimol dose (0.75 mg/kg) was chosen because it has been shown previously to reduce EtOH drinking (Quoilin and Boehm, 2016) but was not expected to produce locomotor effects in the absence of co-administration of EtOH (Holstein et al., 2009; Shen et al., 1998) . Muscimol was dissolved in 0.9% saline and administered i.p. (injection volume 0.01 ml/g). All mice in a squad (8 mice/squad) were first injected with muscimol, and then, all mice were injected with EtOH. Time between muscimol and EtOH injections for each animal was approximately 4 minutes which is similar to previous studies (Holstein et al., 2009 ). In contrast, in Experiment 1, pBBG was administered 2 hours prior to EtOH injection to allow for MG accumulation. EtOH (Deacon Laboratories Inc., King of Prussia, PA) was dissolved in saline (20% v/v) and administered i.p. at a dose of 0, 0.5, 1.0, 1.5, 2.0, or 2.5 g/kg. This dose range was chosen to encompass both locomotor stimulatory and sedative effects.
Experiment 1: pBBG Effects on EtOH Locomotor and Anxiolytic Response
A total of 144 mice were used (n = 12/drug/EtOH dose) for this experiment. Mice were pseudorandomly assigned to a pretreatment group of either pBBG or vehicle (8% DMSO/18% Tween 80/saline), and an EtOH dose group (0 [saline], 0.5, 1.0, 1.5, 2.0, or 2.5 g/ kg). Squads of 8 mice were injected with their assigned pretreatment compound and returned to the home cage for 2 hours. We have previously used the 2-hour time point because it is believed to allow for the accumulation of behaviorally relevant MG concentrations in the brain (Distler et al., 2012 (Distler et al., , 2013 and critically because it was used in the studies that showed inhibition of EtOH drinking following pBBG pretreatment (McMurray 2017) . Two hours later, mice were injected i.p. with their assigned EtOH dose and immediately placed in the activity chambers for 30 minutes.
Experiment 2: Muscimol Effects on EtOH Locomotor and Anxiolytic Response
A total of 142 mice were used (n = 11 to 12/drug/EtOH dose) for this experiment. Mice were pseudorandomly assigned to a pretreatment group of either the GABA A agonist muscimol or vehicle (saline) and an EtOH dose group (0 [saline], 0.5, 1.0, 1.5, 2.0, or 2.5 g/ kg). Squads of 8 mice were injected with their assigned pretreatment compound immediately before a second injection of EtOH, as described in Experiment 1. Mice were then immediately placed in the activity chambers for 30 minutes.
Experiment 3: EtOH Locomotor and Anxiolytic Response in Glo1 Transgenic Mice
A total of 152 male and female Glo1 overexpressing mice and wild-type littermates were used in this experiment (n = 6 to 14/genotype/dose). Wild-type FVB mice show locomotor stimulation at higher EtOH doses than B6 mice (Metten et al., 2004) , so we extended the tested dose range to 3 g/kg to capture more of the dose-response curve. Mice were pseudorandomly assigned to an EtOH dose group (0 [saline], 0.5, 1.0, 1.5, 2.0, 2.5, or 3.0 g/kg). Squads of 8 mice were injected with EtOH and immediately placed in the activity chambers for 30 minutes.
Statistical Analyses
Locomotor activity was analyzed as total distance traveled in 30 minutes, and as a total of 6 bins of 5 minutes each to assess drug and time course interactions (Experiments 1 and 2). Statistical analyses were performed in SPSS (version 24; IBM Corp., Armonk, NY). Total distance data were analyzed by 2-way analysis of variance (ANOVA) with the between-groups factors of drug (pBBG vs. vehicle or muscimol vs. vehicle) and EtOH dose (0, 0.5, 1.0, 1.5, 2.0, and 2.5 g/kg) for Experiments 1 and 2, and genotype (transgenic vs. wild type) and EtOH dose (0, 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0 g/kg) for Experiment 3. Significant interactions were followed up by 1-way ANOVAs; post hoc Dunnett's tests were also used to compare EtOH doses to the saline-treated group. Time course data were analyzed using a 2-way mixed-model ANOVA with between-groups factors of drug (pBBG vs. vehicle or muscimol vs. vehicle) and EtOH dose (0, 0.5, 1.0, 1.5, 2.0, and 2.5 g/kg), and with time as a within-subjects repeated measure (6 total bins of 5 minutes each). A Huynh-Feldt correction was used for repeated measures ANOVA where appropriate. Significant interactions were followed up by lower order ANOVAs. Center times were converted to a percent of total test time and were analyzed using 2-way ANOVA. Significant interactions were followed up by 1-way ANOVAs, and post hoc Dunnett's tests were also used to compare EtOH doses to the salinetreated group. Significance was set at a = 0.05 for all tests.
We could not compare pBBG to muscimol because Experiments 1 and 2 were performed separately and because both pretreatment time (2 hours vs. 0 minutes) and the vehicle solution were different. Figure 1 shows total distance traveled after each EtOH dose for pBBG-and vehicle-treated mice. Statistical analyses showed a main effect of EtOH dose, F(5, 143) = 31.11, p < 0.001, but no main effect of drug or a significant drug 9 EtOH dose interaction. Dunnett's post hoc tests comparing each EtOH dose to saline (collapsed on drug) showed that the 1 and 1.5 g/kg doses of EtOH produced a significant locomotor stimulatory effect (p = 0.005 and p = 0.021, respectively). In contrast, the 2 and 2.5 g/kg doses of EtOH produced significant locomotor sedation compared to saline (p < 0.001 for both). Figure 2A -F shows the time course of locomotor activity for pBBG-and vehicle-treated animals at each EtOH dose. Mixed-model ANOVA showed a main effect of time, F(3.19, 421.41) = 292.24, p < 0.001, and a significant time 9 EtOH dose interaction, F(15.96, 421.41) = 7.5, p < 0.001. There was no significant time 9 drug 9 EtOH dose interaction or time 9 drug interaction. Because of our a priori interest in potential differences in pretreatment effects at sedative versus stimulatory EtOH doses, we chose to examine each EtOH dose individually. There was no main effect of drug and no significant time 9 drug interaction found for any dose of EtOH (p ≥ 0.29 for all), indicating that pBBG treatment did not alter EtOH locomotor response at any time point or EtOH dose (see Fig. 2 ). Figure 3 shows the percent of total time spent in the center region after each EtOH dose for pBBG-and vehicle-treated mice. Time course center time data and analyses are shown in Fig. S1 . Statistical analyses showed a main effect of EtOH dose, F(5, 144) = 10, p < 0.001, and a significant EtOH dose 9 drug interaction, F(5, 144) =2.53, p = 0.032. Follow-up ANOVAs showed a main effect of drug only for the 0 g/kg EtOH dose group (saline control), where pBBG-treated mice spent significantly more time in the center than the vehicle-treated mice, F(1, 24) = 11.17, p = 0.003. analyses showed a main effect of drug, F(1, 142) = 7.76, p < 0.001, a main effect of EtOH dose, F(5, 142) = 14.04, p < 0.001, and a significant drug 9 EtOH dose interaction, F(5, 142) = 2.86, p < 0.017. Follow-up ANOVAs were used to assess the effect of EtOH dose within the muscimol and vehicle groups separately. Both the vehicle and muscimol groups showed a main effect of EtOH dose, F(1, 71) ≥ 4.9, p ≤ 0.001. However, we observed significant locomotor stimulation at the 1 g/kg dose in the vehicle group (1 g/kg >saline, p = 0.015) that was not present in the muscimol-treated animals (p = 0.23). Furthermore, the 2.5 g/kg EtOH dose produced a sedative effect in the muscimol-treated group (p < 0.001) but not in the vehicle-treated group (p = 0.83). Figure 5A -F shows the time course of locomotor activity for muscimol-and vehicle-treated animals at each EtOH dose. Mixed-model ANOVA showed a main effect of time, F(3.74, 486.48) = 275.44, p < 0.001, a significant time 9 drug interaction, F(3.74, 486.48) = 6.03, p < 0.001, and a significant time 9 EtOH dose interaction, F(16.76, 486.48) = 2.64, p < 0.001. There was also a trend toward a significant 3-way interaction of time 9 drug 9 EtOH dose, F(18.71, 486.48) = 1.53, p = 0.073. Due to our a priori interest in individual EtOH dose effects (sedative vs. stimulatory), we chose to follow-up this suggestive 3-way interaction by examining the effects of time and muscimol within each EtOH dose group. The 0 g/kg (saline), 0.5 g/kg, and 2 g/kg EtOH dose groups showed main effects of time, F(2.84-5, 62.45-105) ≥ 36.91, p < 0.001, but no time 9 drug interactions and no main effects of drug. The 1 g/kg EtOH dose group also showed a main effect of time, F(3.53, 77.68) = 62.34, p < 0.001, and no main effect of drug, although there was a trend toward a significant time 9 drug interaction, F(2.89, 77.68) = 2.59, p = 0.063. The 1.5 g/kg EtOH dose group showed a main effect of time, F(4.37, 96.12) = 53.97, p < 0.001, no main effect of drug, and a significant time 9 drug interaction, F(4.37, 6.12) = 6.24, p < 0.001. Follow-up ANOVAs for each time bin found that muscimol-treated mice had significantly less locomotor activity during the 10-and 15-minute time bins than vehicle-treated mice ( Fig. 5D ; main effect of drug, F(1, 24) = 12.61, p = 0.002 and F(1, 24) = 8.21, p = 0.009, respectively). The 2.5 g/kg EtOH dose group also showed a trend toward a significant time 9 drug interaction, F(3.82, 83.82) = 2.5, p = 0.051, and main effects of both time and drug, F(2.81, 83.82) = 30.06, p < 0.001 and F(1, 22) = 36.88, p < 0.001, respectively, with muscimoltreated animals showing significantly more locomotor sedation than vehicle-treated animals for all but 1 time point, Fig. 5F ; F(1, 24) ≥ 10.55, p ≤ 0.004. Figure 6 shows the percent of total time spent in the center region after each EtOH dose for muscimol-and vehicletreated mice. Time course center time data and analyses are shown in Fig. S2 . One muscimol-treated animal in the 2 g/ kg EtOH group was excluded as an outlier (center time >3 standard deviations from the mean). Statistical analyses showed main effects of EtOH dose and drug, F(5, 141) = 5.77, p < 0.001 and F(1, 141) = 4.7, p = 0.032, respectively, and a significant EtOH dose 9 drug interaction, F(5, 141) = 3.06, p = 0.012. Follow-up ANOVAs showed a main effect of drug for the 2.5 g/kg EtOH group, F(1, 24) = 4.77, p = 0.04, and a trend toward a main effect for the 0.5 g/kg EtOH group, F(1, 23) = 3.46, p = 0.077. For the 2.5 g/kg EtOH group, the muscimol-treated mice spent more time in the center than the vehicle-treated mice. However, caution must be used when interpreting this difference due to the profound locomotor sedation seen in the muscimol-treated mice in this dose group; while there were no statistical outliers, 8 of 12 muscimol-treated mice in the 2.5 g/kg EtOH group spent at least 10 consecutive minutes with no locomotor activity, suggesting significant sedation that would interfere with the expression of anxiety-like behavior in this test. dose, F(6, 152) = 11.77, p < 0.001, but no main effect of genotype and no significant interactions. Because there were no significant interactions between sex and other variables, all data are presented collapsed on sex. Dunnett's post hoc tests showed that there was significant locomotor stimulation at the 1.5, 2.0, and 2.5 g/kg EtOH doses as compared to saline (p ≤ 0.003 for all). Figure 8 shows percent of total time spent in the center after each EtOH dose for Glo1 overexpressing mice and wild-type littermates. Time course center time data and analyses are shown in Fig. S3 . Statistical analyses showed a main effect of EtOH dose, F(6, 152) = 2.80, p = 0.013, but no significant interactions. Dunnet's post hoc tests showed a significant anxiolytic effect of EtOH at the 3 g/kg dose (p = 0.037).
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DISCUSSION
We found that a dose of the GLO1 inhibitor pBBG (7.5 mg/kg) that is within the effective range for reducing EtOH drinking did not alter the EtOH locomotor dose-response curve and had no effect on locomotor behavior when administered alone. In contrast, a dose of muscimol that has also been shown to reduce EtOH consumption did produce significant changes in the locomotor response to EtOH (attenuated stimulatory response and potentiated sedative response). Like pBBG, the dose of muscimol we used did not produce locomotor effects in the absence of EtOH. These findings suggest that unlike the GABA A receptor agonist muscimol, pBBG does not alter either the locomotor stimulant or depressant effects of EtOH. Further supporting these findings, Glo1 transgenic mice showed locomotor responses that were similar to wild-type littermates following a range of EtOH doses. These mice were of a different genetic background (FVB vs. B6), so direct comparisons with the pharmacological experiments are somewhat complicated. However, the similar pattern of results between Experiments 1 and 3 (i.e., no effect of GLO1 inhibitor treatment or genetic overexpression of Glo1) does suggest that these findings generalize across genotypes. This absence of an effect of GLO1 manipulations on EtOH locomotor response, especially EtOH locomotor sedation, is surprising given the considerable literature showing that other GABAergic drugs act synergistically with EtOH to potentiate sedative effects (e.g., Dudek and Phillips, 1989; Holstein et al., 2009; Saeed Dar, 2006; Tran et al., 2017; Vanover et al., 1999) .
Although both pBBG and muscimol modulate GABAergic signaling, there are a number of important differences between them which may explain the differences in their interaction with EtOH. MG is a competitive partial agonist at GABA A receptors (Distler et al., 2012) , whereas muscimol is a competitive full agonist at GABA A receptors (Arnt et al., 1979; Kemp et al., 1986) . In addition, MG and muscimol likely have different GABA A receptor subtypes specificity. Another difference is that treatment with pBBG causes the accumulation of MG that is proportionate to local glycolytic activity, whereas muscimol concentrations are expected to be uniform throughout the brain. These differences may explain why GLO1 inhibition (and the resulting elevation of MG) does not produce the additive effect with EtOH that was observed following muscimol pretreatment. Previous studies have shown that neither pBBG treatment nor direct MG administration potentiated other effects of EtOH; specifically, 50 mg/kg MG co-administered with 1.25 g/kg EtOH did not produce an increase in EtOH-induced ataxia as compared to EtOH administered alone. Similarly, 2 doses of pBBG shown to reduce drinking (6.25 and 12.5 mg/kg) did not alter either EtOH-induced ataxia or the duration of EtOH-induced loss of righting reflex (McMurray et al., 2017) . Blood EtOH concentrations were not measured in these experiments, but muscimol has not been reported to alter EtOH metabolism; pBBG effects on EtOH metabolism have not been directly tested, but mice with reduced Glo1 expression (which show a similar reduction in EtOH consumption as pBBG-treated mice) do not differ in EtOH metabolism (McMurray et al., 2017) . We therefore do not believe that differences in EtOH metabolism are likely to explain the observed differences in effects between pBBG and muscimol. Another possible explanation for the differences between pBBG and muscimol is that pBBG was injected 2 hours before EtOH treatment, whereas muscimol was injected immediately before EtOH injection. Although this procedural difference is somewhat confounding, we chose these pretreatment times because they match the conditions used to inhibit EtOH drinking and because they did not produce changes in locomotor activity in the absence of EtOH. However, the gradual buildup of MG following pBBG pretreatment versus the rapid onset of muscimol's effects could explain the different interactions with EtOHinduced locomotor behavior.
Locomotor activity appeared to be lower in Experiment 1 than in Experiment 2 across all EtOH doses, particularly in the vehicle groups. There were several procedural differences between the 2 studies that might explain these differences. First, the vehicle solution used in Experiment 1 (DMSO/ Tween 80/saline) was different from the vehicle solution used in Experiment 2 (normal saline). The concentrations of DMSO and Tween 80 used in Experiment 1 (8 and 18%, respectively) are well below concentrations that have been previously reported to reduce locomotor activity in mice (Castro et al., 1995) , but it remains a formal possibility that the difference in vehicle solution caused the differences in locomotor response among vehicle-treated animals. Additionally, as discussed above, mice in Experiment 1 had a longer pretreatment period (2 hours) as compared to mice in Experiment 2, which could also have contributed to differences in locomotor response to EtOH. EtOH locomotor effects in B6 mice can be surprisingly variable. For example, a 2 g/kg dose of EtOH has been shown to produce locomotor stimulation (Lessov et al., 2001) , sedation Phillips and Dudek, 1991; Sharko and Hodge, 2008) , and no effect (Camarini and Hodge, 2004; Mel on and Boehm, 2011; Phillips et al., 1995; Rose et al., 2013) , and even 2.5 g/kg does not always produce locomotor sedation (e.g., Hilbert et al., 2013) . Therefore, although the differences in vehicle groups are somewhat perplexing, the most relevant comparisons are between each drug and its corresponding vehicle group, as all mice in the same experiment received comparable treatments. At all EtOH doses tested, the vehicle-treated animals still showed sufficient locomotor activity to see a potentiation of sedative effects had one been present. Therefore, we do not believe that group differences are being masked by a floor effect and the apparent differences in locomotor activity between Experiments 1 and 2 are unlikely to undermine our primary conclusions.
Neither pBBG nor muscimol had any systematic effect on EtOH's anxiolytic effects. Similarly, Glo1 transgenic mice did not differ from wild-type mice in EtOH anxiolytic response. However, interpretation of these findings should be made cautiously given there was little evidence of an anxiolytic effect of EtOH alone in these experiments and some doses of EtOH appeared to reduce time spent in the center. Anxiety and locomotor activity can be extremely difficult to untangle due to the activity-dependent nature of the anxiety variables used (e.g., movement into/out of an "anxiogenic" region of the apparatus) (Milner and Crabbe, 2008) . Therefore, the observed differences in locomotor behavior across dose groups may have confounded the anxiety results. For example, an increase in center time was seen in the 2.5 g/kg-treated muscimol group in Experiment 2. Upon closer examination of the data, many mice were clearly sedated (no activity for ≥10 minutes) and thus spent more time in the center of the open field. Therefore, even an apparent "anxiolytic" effect of EtOH is complicated by the locomotor sedative effects. EtOH has been shown to be anxiolytic in B6 mice at doses within the range used here (e.g., Boyce-Rustay et al., 2007; Gulick and Gould, 2009 ), However, these studies have used assays optimized for assessing anxiety-like behavior such as the elevated plus maze, and to our knowledge, this effect has not been seen in the open field test we used here. Consequently, there may be apparatus-specific effects in EtOH anxiolytic response that are not apparent in the present experiments. However, we did observe a significant anxiolytic effect of pBBG treatment at baseline (0 g/kg EtOH), consistent with previous findings, but at a much lower dose of pBBG than has been seen before (50 mg/kg; Distler et al., 2012) .
Although the GLO1 inhibitor did not produce the classically observed synergistic effect on locomotor sedation observed with other GABAergic drugs, it is possible that there are other additive effects with EtOH. For example, other drugs that increase GABAergic activity (e.g., barbiturates, benzodiazepines, neuroactive steroids) substitute for EtOH in drug discrimination procedures (Kostowski and Bie nkowski, 1999; Shannon et al., 2004) . Thus, increased MG activation of GABA A receptors due to GLO1 inhibition may still produce interoceptive effects that are similar to EtOH itself. In this case, we might expect that GLO1 inhibitors decrease EtOH consumption by acting additively with EtOH in such a way that mice do not need to consume as much to achieve the same interoceptive effects.
In summary, we have shown that a dose of pBBG within the range that has been previously shown to reduce bingelike EtOH drinking does not alter sensitivity to EtOH locomotor stimulation or sedation, despite its presumed GABAergic mechanism of action. This is in direct contrast to our findings with the GABA A agonist muscimol, which attenuated the locomotor stimulatory response to EtOH and potentiated the sedative effect. This result suggests that EtOH drinking is not reduced by pBBG because it interferes with consumption by potentiating the sedative effects. Instead, GLO1 inhibition may reduce drinking by altering the rewarding or aversive properties of EtOH, a possibility that we are currently investigating. Overall, the lack of potentiation of EtOH's locomotor effects seen with GLO1 inhibition suggests a mechanism that is qualitatively distinct from direct GABA agonists and modulators and provides further support for the therapeutic potential of targeting this system in AUD.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article: Fig. S1 . Time course of center time by EtOH dose for pBBG-and vehicle-treated groups. There was no significant 3-way interaction of time 9 EtOH dose 9 drug group, but there was a main effect of time, F(3.67, 483.29) = 3.02, p = 0.021, and a significant time 9 EtOH dose interaction, F(18.31, 483.29) = 4.48, p < 0.001. Fig. S2 . Time course of center time by EtOH dose for muscimol-and vehicle-treated groups. There was no significant 3-way interaction of time 9 EtOH dose 9 drug group, but there was a main effect of time, F(3.85, 500.12) = 7.02, p < 0.001, and significant time 9 EtOH, F(3.95, 500.12) = 4.48, p = 0.002, and time 9 drug group interactions, F(17.21, 500.12) = 2.29, p = 0.002. Fig. S3 . Time course of center time by EtOH dose for Glo1 TG and wild-type (WT) mice. There were no main effects and no significant interactions.
